Interestingly, our analysis of large-cell neuroendocrine carcinoma (LCNEC) samples revealed that loss of PTEN and PHLDA3 often occurs in the same tumors, and these losses have an additive effect on AKT activation [5]. This evidence concerns the gene AKT1 and large cell neuroendocrine carcinoma.